The study, published in BMC Cancer by a team led by Susanne von Kroge of University Medical Center Hamburg-Eppendorf together with collaborators at the Robert Koch Institute and the Hamburg Cancer Registry, drew on harmonized nationwide registry data covering the years 2020 through 2023, with vital status follow-up extending to December 2024. From a total of 16,443 patients diagnosed with a first primary diffuse large B-cell lymphoma, 10,872 began systemic therapy within 56 days of diagnosis and formed the primary analysis cohort. The median age was 71 years, 44.2 percent of patients were female, and the median follow-up lasted about a year and a half.

The researchers divided patients into groups according to the diagnosis-to-treatment interval, a measure epidemiologists call the DTI, ranging from treatment in the first week after diagnosis to initiation between weeks five and eight. Three-year overall survival across these five groups ranged from roughly 63 percent to 75 percent. On its face, that spread might seem to suggest that timing matters enormously. But when the team applied statistical models, the direction of the association was the opposite of what the urgency narrative would predict.

Using Kaplan-Meier survival curves and Cox proportional hazards regression, the investigators found that compared with patients treated in week one, those who started later had progressively lower hazards of death. Patients beginning therapy in week three had a 28 percent lower hazard of dying from any cause, with a hazard ratio of 0.72 and a 95 percent confidence interval of 0.64 to 0.81. Those starting in week four fared better still, at a hazard ratio of 0.63, and patients treated between weeks five and eight showed a hazard ratio of 0.62, or a 38 percent reduction. The confidence intervals in every case excluded one, indicating the associations were statistically robust.

To a clinician, such a pattern immediately raises a red flag of confounding. Doctors do not assign treatment dates at random. Patients with the most aggressive, bulky, or symptomatic disease are rushed into the infusion chair within days, while those with more indolent-appearing disease can safely wait for complete staging, cardiac assessments, and fertility discussions. If sicker patients are treated fastest, then early treatment will appear to worsen survival even if timing itself has no causal effect, a classic example of what epidemiologists call confounding by indication, or in this context, the waiting-time paradox.

The German team addressed this head-on by adjusting their models for patient, tumor, and structural characteristics, most importantly the International Prognostic Index, or IPI, the standard five-factor score that combines age, disease stage, number of extranodal sites, performance status, and lactate dehydrogenase levels. Low-risk IPI strongly predicted better survival, with a hazard ratio of 0.24 compared with high-risk disease. Even after this adjustment, a residual association between longer diagnosis-to-treatment intervals and improved survival persisted, hinting that the interval itself might carry independent prognostic information in patients with less aggressive disease.

Perhaps the most revealing part of the study is what predicted delay in the first place. The researchers modeled which factors pushed treatment later and found that low-risk IPI scores added an average of 7.89 days to the interval, while older age added 0.62 days per standard deviation. Patients who survived the first year had, on average, started treatment 3.26 days later than those who did not. In other words, the patients who waited longest were systematically the ones with the least threatening disease, and the ones treated most urgently were those whose lymphoma demanded immediate action.

Missing IPI data posed a methodological challenge that the authors handled with unusual care. Rather than discarding incomplete records, they treated missing IPI as a separate category and ran both complete-case and multiple-imputation sensitivity analyses to test whether their conclusions depended on how missingness was handled. The consistency of the results across these approaches strengthens the central finding that early initiation is primarily a marker of adverse disease biology rather than a driver of survival in its own right.

The implications for health policy and clinical practice are subtle but significant. In many healthcare systems, time-to-treatment is used as a quality indicator, with targets and audits pressing hospitals to start cancer therapy faster. For solid tumors with validated screening pathways, such metrics can be meaningful. But this study suggests that for diffuse large B-cell lymphoma, raw speed from diagnosis to treatment is a poor proxy for quality of care. Penalizing centers for longer intervals could perversely reward the triage of less sick patients while doing nothing for those with aggressive disease, who are already treated within days.

The authors conclude that early treatment in newly diagnosed DLBCL is primarily driven by adverse disease characteristics, and that the diagnosis-to-treatment interval may function as an independent prognostic factor mainly in less aggressive disease. The study was funded by the Innovationsfonds zur Förderung von Versorgungsforschung under grant number 01VSF25057, and the underlying data came from German state cancer registries used under legal provisions permitting scientific analysis of non-identifiable records. For the roughly 16,000 Germans diagnosed each year with this lymphoma, and for oncologists everywhere who feel the pressure of the clock, the message is a nuanced one: the calendar matters less than the biology, and a few extra days of careful preparation may be exactly what the least aggressive tumors allow, and what the most aggressive ones cannot afford.

Subject of Research: The association between the diagnosis-to-treatment interval and survival in newly diagnosed diffuse large B-cell lymphoma

Article Title: Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study

Article References: von Kroge, S., Steinhaus, N. J., Bokemeyer, C., Tetzlaff, F., Walk, H., Kusche, H., LYSED study group, Klotz, S., Obi, N., Knesebeck, O. V., Beernink, M., Gundler, C., Ückert, F., Schulze, K., Augustin, J., Semmelhaack, R., Sassenberg-Gummert, A., & Peters, F. (2026). Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study. BMC Cancer, 26(1), Article 1144. https://doi.org/10.1186/s12885-026-17024-9

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17024-9

Keywords: diffuse large B-cell lymphoma, diagnosis-to-treatment interval, treatment delay, immunochemotherapy, survival, International Prognostic Index, cancer registry, Cox regression, prognostic markers, waiting-time paradox, hematology, oncology

Diffuse large B-cell lymphoma, or DLBCL, is the most frequent subtype of non-Hodgkin lymphoma, accounting for approximately 30 to 40 percent of all cases. For two decades, the frontline standard of care was R-CHOP, a five-drug immunochemotherapy combining the monoclonal antibody rituximab with three chemotherapeutic agents and a corticosteroid. Despite countless attempts to improve upon it with novel agents, R-CHOP remained essentially unchallenged until the POLARIX trial demonstrated that swapping vincristine for polatuzumab vedotin—a targeted antibody-drug conjugate directed against CD79b, a signaling component of the B-cell receptor—produced significantly superior outcomes. That result transformed Pola-R-CHP into the new global standard for previously untreated DLBCL, and the regimen was approved in China in April 2023 for adult patients.

Yet the POLARIX trial enrolled only patients with international prognostic index scores of 2 through 5, meaning patients considered to have intermediate or high-risk disease. The IPI is a well-established scoring system that predicts prognosis in DLBCL using five factors: age, tumor stage, number of extranodal sites involved, performance status, and serum lactate dehydrogenase levels. Patients scoring 0 or 1 are conventionally labeled low-risk and represent approximately 30 percent of newly diagnosed cases. Because they were excluded from the pivotal trial, this substantial population became a critical evidence gap. The problem is compounded by the fact that low IPI scores do not guarantee biological simplicity. Many of these patients carry molecular and pathological features known to undermine standard therapy, including bulky tumors, double-expressor lymphoma, and abnormalities of the TP53 gene, the so-called guardian of the genome.

The new study, led by Yuhong Ren and Peng Liu of Zhongshan Hospital, Fudan University, together with colleagues across China, set out to fill that gap using real-world data. Between June 2023 and July 2025, the researchers enrolled 118 consecutive previously untreated DLBCL patients with IPI scores of 0 or 1 who received at least one cycle of Pola-R-CHP. The median age was 53.5 years, with patients ranging from 17 to 87 years old. Despite their formally low-risk classification, the cohort was biologically heterogeneous and carried a surprising burden of adverse features: 51.7 percent had the non-germinal center B-cell-like subtype, 24.6 percent had double-expressor lymphoma, 9.3 percent had double-hit or triple-hit lymphoma, 25.4 percent showed high P53 expression, 12.7 percent had bulky disease, and 62.7 percent had extranodal involvement.

The treatment protocol followed a well-defined structure. Each 21-day cycle comprised polatuzumab vedotin at 1.8 milligrams per kilogram of body weight, rituximab at 375 milligrams per square meter, cyclophosphamide at 750 milligrams per square meter, doxorubicin at 50 milligrams per square meter or epirubicin at 70 milligrams per square meter, and prednisone at 100 milligrams orally for five consecutive days. Patients received a median of six cycles. Efficacy was assessed using whole-body fluorodeoxyglucose PET/CT or contrast-enhanced CT imaging after three to four cycles and again at the end of treatment, with responses graded according to the 2014 Lugano classification, the international standard for lymphoma response assessment.

The results were remarkable. Among the 68 patients who had completed end-of-treatment evaluation at the data cut-off of August 2025, 63 achieved a complete response, yielding a complete response rate of 92.6 percent. The overall response rate reached 98.5 percent at end of treatment and 98.9 percent at interim assessment, with 78.2 percent of interim-evaluated patients already in complete remission after just three to four cycles. Only two patients experienced disease progression during follow-up, both of whom had central nervous system involvement, and no deaths occurred at a median follow-up of 7.1 months. Importantly, the 50 patients without end-of-treatment assessment had not progressed, died, or been lost to follow-up; they were simply still undergoing treatment or awaiting imaging, meaning the missing data reflected short follow-up rather than treatment failure.

Perhaps most striking was the consistency of responses across molecular subgroups. Exploratory analyses showed broadly similar response rates at both interim and end-of-treatment time points among elderly patients, those with the non-germinal center subtype, extranodal disease, double-expressor lymphoma, and double-hit or triple-hit lymphoma. The one exception was the high P53 expression subgroup, where the complete response rate was numerically lower at 78.6 percent compared with 96.9 percent in patients with low or absent P53 expression. This finding aligns with the well-documented biology of TP53 alterations, which are associated with genomic instability and chemoresistance in lymphoma. However, the researchers caution that the small number of evaluable patients in this subgroup prevents definitive conclusions, and they suggest that the bystander effect of antibody-drug conjugates—the ability of the drug payload to diffuse into neighboring tumor cells that may not express the target antigen—could theoretically help overcome the clonal heterogeneity that drives resistance.

Safety data from all 118 patients showed a tolerable profile without unexpected toxicity compared with the POLARIX trial. Any grade 3 or 4 adverse event occurred in 24.6 percent of patients. The most common adverse events overall were anemia in 68.6 percent, leukopenia in 47.5 percent, and decreased neutrophil count in 39.8 percent, the vast majority of which were mild to moderate. The most frequent severe toxicity was neutropenia, affecting 21.2 percent of patients at grade 3 or 4—a manageable side effect routinely addressed with dose adjustments and growth factor support in clinical practice. No new safety signals emerged, reinforcing the regimen’s established risk-benefit profile in a broader and more diverse population than the original trial captured.

The study’s authors place their findings in context by comparing them with other real-world cohorts and historical R-CHOP data. Published complete response rates for frontline Pola-R-CHP and R-CHOP in low-risk patients range from 80.6 to 96.5 percent, and the current results sit comfortably at the upper end of that spectrum. Notably, the Chinese cohort carried a heavier burden of adverse features than a comparable R-CHOP cohort from a Chinese phase 3 trial, with higher rates of impaired performance status, advanced stage disease, and double-expressor lymphoma, yet still achieved outstanding responses. The researchers acknowledge the inherent limitations of a retrospective, single-arm design conducted exclusively in China, including potential selection bias and immature survival data, and they emphasize that a conservative sensitivity analysis counting all unevaluated patients as non-responders still yielded a complete response rate of 85.1 percent.

The implications reach beyond the numbers. Roughly a third of DLBCL patients worldwide fall into the IPI 0-1 category, yet they remain underrepresented in clinical trials and continue to experience late relapses even in limited-stage disease, a pattern that contrasts with the survival plateau seen in advanced-stage patients. This study provides the first multicenter real-world evidence that Pola-R-CHP is both effective and tolerable in this population, even when adverse biological features are present. The authors call for prospective randomized trials to precisely define the magnitude of benefit, and for molecular subtyping strategies to better identify which low-risk patients harbor hidden resistance mechanisms. For now, the message for clinicians is clear: the antibody-drug conjugate revolution in lymphoma treatment appears to extend to nearly every patient who walks through the door, not just those who fit the narrow criteria of a registration trial.

Subject of Research: Frontline Pola-R-CHP treatment of low-risk diffuse large B-cell lymphoma

Article Title: Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China

Article References: Ren, Y., Liu, J., Lin, Z., Shou, L., Zeng, H., Wu, D., Zeng, Z., Zhou, F., Bao, L., Jing, H., Jiang, S., Liu, H., Shen, J., Yu, W., Zhou, H., Xu, J., Zhang, Y., Wang, T., Huang, H., … Liu, P. (2026). Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China. Clinical Cancer Bulletin, 5(1), Article 21. https://doi.org/10.1007/s44272-026-00073-3

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00073-3

Keywords: diffuse large B-cell lymphoma, Pola-R-CHP, polatuzumab vedotin, antibody-drug conjugate, international prognostic index, real-world study, R-CHOP, double-expressor lymphoma, TP53, complete response, non-Hodgkin lymphoma, immunochemotherapy